You have read all your free articles, to continue reading subscribe to read the rest of this content.
Involving patients earlier in the development of new treatments and drugs is becoming a more highlighted issue. Recent survey findings and reports show that Swedish patients are more likely to experience problems due to inadequate coordination of their care than patients in many other countries ,Already a subscriber Login You…
The company has announced preliminary data from the LPC-004 study that aimed to determine the tolerability of Liproca Depot and the Prostate-Specific Antigen (PSA) effect at month 5 on patients in part II of the study. The PSA reduction for part II patients was in line with the expected pattern…
Betagenon/Baltic Bio announces positive results from a 28 day Phase IIa trial of the first-in-class AMPK activator. The main study results are not yet finalized but review of the initial data showed that a number of patients who were included based on HbA1c at screening, had FPG below 7 mM…
Ultimovacs has announced that the first patient has been randomized in the LUNGVAC study. The study in non-small cell lung cancer (NSCLC) is the fifth Phase II clinical trial in which the universal cancer vaccine, UV1, is being investigated in combination with checkpoint inhibitors. The LUNGVAAlready a subscriber Login You…
